Cargando…

Absence of BCL-2 Expression Identifies a Subgroup of AML with Distinct Phenotypic, Molecular, and Clinical Characteristics

Acute myeloid leukemia (AML) is a hematologic malignancy characterized by the rapid and uncontrolled clonal growth of myeloid lineage cells in the bone marrow. The advent of oral, selective inhibitors of the B-cell leukemia/lymphoma-2 (BCL-2) apoptosis pathway, such as venetoclax, will likely induce...

Descripción completa

Detalles Bibliográficos
Autores principales:	haes, Inke De, Dendooven, Amélie, Mercier, Marie Le, Puylaert, Pauline, Vermeulen, Katrien, Kockx, Mark, Deiteren, Kathleen, Maes, Marie-Berthe, Berneman, Zwi, Anguille, Sébastien
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7599534/ https://www.ncbi.nlm.nih.gov/pubmed/32992732 http://dx.doi.org/10.3390/jcm9103090

Ejemplares similares

Interferon α may be back on track to treat acute myeloid leukemia
por: Smits, Evelien L.J.M., et al.
Publicado: (2013)

Short-term cultured, interleukin-15 differentiated dendritic cells have potent immunostimulatory properties
por: Anguille, Sébastien, et al.
Publicado: (2009)

Poly(I:C) Enhances the Susceptibility of Leukemic Cells to NK Cell Cytotoxicity and Phagocytosis by DC
por: Lion, Eva, et al.
Publicado: (2011)

Safety and Efficacy of Antibiotic De-escalation and Discontinuation in High-Risk Hematological Patients With Febrile Neutropenia: A Single-Center Experience
por: Verlinden, Anke, et al.
Publicado: (2021)

Interleukin-15-Cultured Dendritic Cells Enhance Anti-Tumor Gamma Delta T Cell Functions through IL-15 Secretion
por: Van Acker, Heleen H., et al.
Publicado: (2018)

Overexpression of FcεRI on Bone Marrow Mast Cells, but Not MRGPRX2, in Clonal Mast Cell Disorders With Wasp Venom Anaphylaxis
por: Elst, Jessy, et al.
Publicado: (2022)

MicroRNAs Distinguish Cytogenetic Subgroups in Pediatric AML and Contribute to Complex Regulatory Networks in AML-Relevant Pathways
por: Daschkey, Svenja, et al.
Publicado: (2013)

BCL2 Inhibition: A New Paradigm for the Treatment of AML and Beyond
por: Wei, Andrew H., et al.
Publicado: (2023)

Two for one: targeting BCMA and CD19 in B-cell malignancies with off-the-shelf dual-CAR NK-92 cells
por: Roex, Gils, et al.
Publicado: (2022)

Dendritic Cell-Based and Other Vaccination Strategies for Pediatric Cancer
por: de Bruijn, Sévérine, et al.
Publicado: (2019)

Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma
por: Roex, Gils, et al.
Publicado: (2020)

The Ins and Outs of Messenger RNA Electroporation for Physical Gene Delivery in Immune Cell-Based Therapy
por: Campillo-Davo, Diana, et al.
Publicado: (2021)

Coordinate PI3K pathway and Bcl-2 family disruption in AML
por: Bose, Prithviraj, et al.
Publicado: (2012)

Transpresentation of interleukin-15 by IL-15/IL-15Rα mRNA-engineered human dendritic cells boosts antitumoral natural killer cell activity
por: Van den Bergh, Johan, et al.
Publicado: (2015)

Interleukin-15 enhances the proliferation, stimulatory phenotype, and antitumor effector functions of human gamma delta T cells
por: Van Acker, Heleen H., et al.
Publicado: (2016)

High-dimensional mass cytometry analysis of NK cell alterations in AML identifies a subgroup with adverse clinical outcome
por: Chretien, Anne-Sophie, et al.
Publicado: (2021)

Correction: Interleukin-15-Induced CD56(+) Myeloid Dendritic Cells Combine Potent Tumor Antigen Presentation with Direct Tumoricidal Potential
por: Anguille, Sébastien, et al.
Publicado: (2014)

Interleukin-15-Induced CD56(+) Myeloid Dendritic Cells Combine Potent Tumor Antigen Presentation with Direct Tumoricidal Potential
por: Anguille, Sébastien, et al.
Publicado: (2012)

Interleukin-15 Dendritic Cells Harness NK Cell Cytotoxic Effector Function in a Contact- and IL-15-Dependent Manner
por: Anguille, Sébastien, et al.
Publicado: (2015)

CD56 Homodimerization and Participation in Anti-Tumor Immune Effector Cell Functioning: A Role for Interleukin-15
por: Van Acker, Heleen H., et al.
Publicado: (2019)

Dendritic Cell-Based Immunotherapy of Acute Myeloid Leukemia
por: Van Acker, Heleen H., et al.
Publicado: (2019)

Rapid Assessment of Functional Avidity of Tumor-Specific T Cell Receptors Using an Antigen-Presenting Tumor Cell Line Electroporated with Full-Length Tumor Antigen mRNA
por: Campillo-Davo, Diana, et al.
Publicado: (2020)

Disease Perception Is Correlated with Health-Related Quality of Life in Patients Suffering from Myelodysplastic Syndromes: Results of the Belgian Be-QUALMS Study
por: Heyrman, Bert, et al.
Publicado: (2023)

Optimizing Dendritic Cell-Based Immunotherapy: Tackling the Complexity of Different Arms of the Immune System
por: Van Brussel, Ilse, et al.
Publicado: (2012)

To the Brain and Back: Migratory Paths of Dendritic Cells in Multiple Sclerosis
por: De Laere, Maxime, et al.
Publicado: (2018)

Chimeric Antigen Receptor-Modified T Cell Therapy in Multiple Myeloma: Beyond B Cell Maturation Antigen
por: Timmers, Marijke, et al.
Publicado: (2019)

Antigen-Specific Treatment Modalities in MS: The Past, the Present, and the Future
por: Derdelinckx, Judith, et al.
Publicado: (2021)

BCL2L10 is a predictive factor for resistance to Azacitidine in MDS and AML patients
por: Cluzeau, Thomas, et al.
Publicado: (2012)

Neuroendocrine Immunoregulation in Multiple Sclerosis
por: Deckx, Nathalie, et al.
Publicado: (2013)

Anti-Tumor Potency of Short-Term Interleukin-15 Dendritic Cells Is Potentiated by In Situ Silencing of Programmed-Death Ligands
por: Versteven, Maarten, et al.
Publicado: (2022)

Plasmid-based genetic modification of human bone marrow-derived stromal cells: analysis of cell survival and transgene expression after transplantation in rat spinal cord
por: Ronsyn, Mark W, et al.
Publicado: (2007)

Maintenance of elderly AML patients with androgens
por: Pigneux, Arnaud, et al.
Publicado: (2017)

Dendritic Cells: Cellular Mediators for Immunological Tolerance
por: Chung, Chun Yuen J., et al.
Publicado: (2013)

Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation
por: Kunadt, Desiree, et al.
Publicado: (2022)

In vitro expansion of Wilms’ tumor protein 1 epitope-specific primary T cells from healthy human peripheral blood mononuclear cells
por: van der Heijden, Sanne, et al.
Publicado: (2023)

Durable remissions with venetoclax monotherapy in secondary AML refractory to hypomethylating agents and high expression of BCL‐2 and/or BIM
por: Huemer, Florian, et al.
Publicado: (2019)

BCL-2 Expression in AML Patients over 65 Years: Impact on Outcomes across Different Therapeutic Strategies
por: Tiribelli, Mario, et al.
Publicado: (2021)

Regulatory T Cells and Human Disease
por: Cools, Nathalie, et al.
Publicado: (2007)

Human Tears Reveal Insights into Corneal Neovascularization
por: Zakaria, Nadia, et al.
Publicado: (2012)

Impact of elevated anti-apoptotic MCL-1 and BCL-2 on the development and treatment of MLL-AF9 AML in mice
por: Anstee, Natasha S., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_9fupsrsfrehmaqi1u7hutjiqj3